Eltrombopag : How secure in triple therapy of HCV ?

Kayar Y., Danalioglu A., Kocaman O., Baysal B., ŞENTÜRK H.

ACTA GASTRO-ENTEROLOGICA BELGICA, cilt.78, sa.4, ss.445-446, 2015 (SCI-Expanded, Scopus) identifier identifier identifier

  • Yayın Türü: Makale / Kısa Makale
  • Cilt numarası: 78 Sayı: 4
  • Basım Tarihi: 2015
  • Dergi Adı: ACTA GASTRO-ENTEROLOGICA BELGICA
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.445-446
  • Bezmiâlem Vakıf Üniversitesi Adresli: Evet

Özet

Triple therapy of hepatitis C usually leads to some hematological and dermatological side effects. Thrombocytopenia is one of the most common side effects that are encountered during triple therapy. Eltrombopag was approved for the treatment of patients with chronic hepatitis C and thrombocytopenia to allow the initiation and maintenance of interferon based therapies. During eltrombopag therapy, some side effects like headache, abdominal pain, and some complications such as portal vein thrombosis, deep vein thrombosis and arterial thrombosis were observed more frequently than placebo. We described here a patient who developing thrombosis secondary to eltrombopag in receiving triple therapy.